Humalog Mix 50

Phase 3

Eli Lilly and Company (LLY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Diabetes Mellitus, Type 1

View Full Landscape

Drug Information

Target Indication

Diabetes Mellitus, Type 1

Clinical Trial

NCT00191581

Last updated: 12/31/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA4/30/1996

Humalog

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Humalog is also indicated for the initial stabilisation of diabetes mellitus.

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

LLY

Eli Lilly and Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

somatropin, rDNA origin, for injectionPhase 3

Growth Disorder

Ultra-Rapid LisproPhase 3

Type 1 Diabetes Mellitus

RetatrutidePhase 3

Obesity

Atomoxetine HydrochloridePhase 3

Attention Deficit Hyperactivity Disorder

LY2216684Phase 3

Major Depressive Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts